Press Releases

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022

JP Morgan Health Care Conference banner
Atomwise Invited to Present at the 2022 J.P. Morgan Healthcare Conference

Leading AI-pharma company among select few private companies to participate San Francisco, CA – January 5, 2022 – Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. […]


January 5, 2022
Atomwise SAB, BOD 2021
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board

Experts include Mike Varney, Bruce Roth, John Hamer, Kemal Malik, and Andrew Lo SAN FRANCISCO, Calif., June 17, 2021 – Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on […]


June 17, 2021
Atomwise Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2021

Recognized for innovation in powering small molecule drug discovery with AI, Atomwise among the Top-10 in Biotechnology category SAN FRANCISCO, Calif. — March 9, 2021 —  Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company’s prestigious annual list of the World’s Most […]


March 9, 2021
Atomwise Announces Growing Portfolio of Joint Venture Companies

Atomwise unveils a growing portfolio of emerging joint venture companies, with programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Atomwise CEO and joint venture companies are scheduled to speak at Informa’s Biotech Showcase from January 11-15, 2021 during J.P. Morgan Healthcare Week. SAN FRANCISCO, Calif., December 21, 2020 – Atomwise, the leader in […]


December 21, 2020
Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December  18, 2020 – Atomwise, the leader in using artificial […]


December 18, 2020